Amgen: $10.4 Billion Q3 Revenue Reflects 8% Growth As Repatha, UPLIZNA And IMDELLTRA Sales Accelerate
· pulse2.com · popularity 17/100 · 0 similar stories today · Entrepreneurship & Startups (Business & Finance)
Read the original at pulse2.com →
Summary
Amgen, a biotechnology company headquartered in Thousand Oaks, California, reported third-quarter 2026 revenue of $10.4 billion, representing an 8% increase from the prior-year period. The company's performance was supported by growth across its commercial portfolio, including increased sales of Repatha, EVENITY, UPLIZNA, TEZSPIRE, and IMDELLTRA. The post Amgen: $10.4 Billion Q3 Revenue Reflects 8% Growth As Repatha, UPLIZNA And IMDELLTRA Sales Accelerate appeared first on Pulse 2.0 .
Found in: Pulse 2.0. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 14.